Stockreport
Vertex Pharma’s three-drug combinations improve breathing in some cystic fibrosis patients [CNBC]
Last vertex earnings: 7/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
PDF
Vertex Pharmaceuticals said Tuesday that its three-drug cocktails improved a measure of lung function in patients with cystic fibrosis by 9.6 percentage points or more, surpassing Wall Street's expectations and setting the company up to advance a medicine to treat thousands more patients with the disease. The Boston-based biotech company is testing multiple combination regimens to find the best cocktail for a majority of patients with cystic fibrosis. Vertex has brought to market medicines for genetic forms of the disease affecting about 30,000 of the 75,000 people with CF worldwide; the majority of patients, though, still have no approved treatment options that target the disease's underlying cause. Cystic fibrosis is a rare, genetic disease that causes mucus to build up in the lungs and other organs, leading to infections, damage and respiratory failure. It's driven by mutations in a gene known as CFTR, and because different mutations manifest in slightly different wa
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | VRTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRTX alerts
VRTX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting VERTEX news events
Weekly update
A roundup of the hottest topics
VRTX
NEWS
NEWS
- Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation[Business Wire]
- Vertex Awards Two College Students Full Scholarships to the University of Massachusetts[Business Wire]
- Vertex cystic fibrosis drug gets expanded approval for use in infants [Reuters (UK)][Reuters]
- Vertex cystic fibrosis drug gets expanded approval for use in infants [Reuters][Reuters]
- FDA OKs expanded use for Vertex Pharma's Kalydeco [Seeking Alpha][Seeking Alpha]
- More
VRTX
SEC Filings
SEC Filings
- 8/7/18 - Form 4
- 8/6/18 - Form 4
- 8/6/18 - Form 4
- VRTX's page on the SEC website
- More